



ZITHROMAX IV
Pfizer
500mg/vial
Powder for Solution
for Infusion
Azithromycin (as azithromycin dihydrate)
Intravenous Use Only
Provides 100mg/ml azithromycin when reconstituted as recommended
10 single use vials

Mockup from
8431283

Controlled Medicine
Ubat Terkawal
Jauhi Ubat Daripada Kanak-Kanak
Keep Medicine Out of Reach of Children
Product Registration Holder:
Pfizer (Malaysia) Sdn. Bhd.
Level 10 & 11,
Wisma Averis, Tower 2,
Avenue 5, Bangsar South,
No. 8 Jalan Kerinchi,
59200 Kuala Lumpur, Malaysia.

Manufactured by
Pharmacia & Upjohn Company LLC
Kalamazoo, USA
under the authority of Pfizer Inc.,
New York, N.Y., USA

Packaged by
Fareva Amboise
Pocé-sur-Cisse, France
under the authority of Pfizer Inc.,
New York, N.Y., USA

BRU10070519P
MAL20032238ARZ

Scan here for package insert



EPI-ZIT-20032238

Read enclosed leaflet before use.
Reconstitute and dilute before use.
ZITHROMAX IV SHOULD NOT BE GIVEN AS A
BOLUS OR AN INTRAMUSCULAR INJECTION.
Infuse over a period of not less than
60 minutes.
Discard any unused solution.
Store below 30°C
Shelf life after reconstitution:
24 hours when stored at 2°C - 8°C.
Keep vial in original packaging until use.



ZITHROMAX IV
500mg/vial
Powder for Solution
for Infusion

Azithromycin (as azithromycin dihydrate)
Intravenous Use Only
Provides 100mg/ml azithromycin when reconstituted as recommended
10 single use vials

Description	ZITHROMAX IV 500 mg B10
Primary market (s)	MYS
Version - Date	V2 - 02/07/2025
Fareva item code	Mockup from 8431283
Template	C383
Dimensions	122 x 51 x 54 mm
Prepared by	Christophe GASSELIN

Colours		Others
Printing	Non-Printing	
Black	Keylines	 Gluing area without varnish and printing
PMS 541 C		
PMS 277 C		
PMS 354 C		
Pantone Rubine Red C		

FAREVA
AMBOISE



Batch No:
Exp. date:
Mfg. date:



WebCenter Approval Information

Project: PAR-2025-1002916
Document: v1-Mockup from 8431283-ZITHROMAX IV x10 MYS.pdf
Document description:
e3_ART - Approval - Date: Jul 7, 2025 at 7:09 PM GMT+08:00
Version: 2
Version ID: 00002_0001514562
Downloaded: Oct 16, 2025 at 1:10 PM GMT+08:00
By: Ibrahim, Siti Khadijah (BINTIS08)
Approval state:

Approved

Sta ge Nr	Approver	Role / Group	Date and Time	Action	Comment
1	NADATH, KRISHNAPRIYA (NADATK), Pfizer (Global)		Jul 4, 2025 at 8:17 PM GMT+08:00	Approved (Stage 1 - P)	
2	Zaman, Aisha (AISHAZ), Pfizer (Global)		Jul 5, 2025 at 9:15 PM GMT+08:00	Approved (Stage 2 - MA)	
2	Ibrahim, Siti Khadijah (BINTIS08), Pfizer (Global)		Jul 7, 2025 at 7:09 PM GMT+08:00	Approved (Stage 2 - MA)	